Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys
- PMID: 8940206
- DOI: 10.1093/infdis/174.6.1176
Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys
Abstract
The feasibility of a purified, inactivated dengue (DEN) vaccine made in Vero cells was explored. A DEN-2 virus candidate was chosen for production of a monotypic, purified, inactivated vaccine (PIV). Virus was harvested from roller bottle culture supernatants, concentrated, and purified on sucrose gradients. The purified virus was inactivated with 0.05% formalin at 22 degrees C. After inactivation, the virus retained its antigenicity and was immunogenic in mice and rhesus monkeys, in which it elicited high titers of DEN-2 virus-neutralizing antibody. Mice were completely protected against challenge with live, virulent virus after receiving two 0.15-microg doses of PIV. Monkeys vaccinated with three doses ranging as low as 0.25 microg demonstrated complete absence or a significant reduction in the number of days of viremia after challenge with homologous virus. These results warrant further testing and development of PIVs for other DEN virus serotypes.
Similar articles
-
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268. Epub 2015 Feb 2. Am J Trop Med Hyg. 2015. PMID: 25646261 Free PMC article.
-
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.Virology. 2002 Jun 20;298(1):146-59. doi: 10.1006/viro.2002.1462. Virology. 2002. PMID: 12093182
-
Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.J Virol. 2001 Sep;75(17):8259-67. doi: 10.1128/jvi.75.17.8259-8267.2001. J Virol. 2001. PMID: 11483771 Free PMC article.
-
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.J Virol. 2000 Jun;74(12):5477-85. doi: 10.1128/jvi.74.12.5477-5485.2000. J Virol. 2000. PMID: 10823852 Free PMC article.
-
Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells.Am J Trop Med Hyg. 1996 Nov;55(5):504-10. doi: 10.4269/ajtmh.1996.55.504. Am J Trop Med Hyg. 1996. PMID: 8940981
Cited by
-
Approaches of dengue control: vaccine strategies and future aspects.Front Immunol. 2024 Feb 29;15:1362780. doi: 10.3389/fimmu.2024.1362780. eCollection 2024. Front Immunol. 2024. PMID: 38487527 Free PMC article. Review.
-
Generation of quality-controlled SARS-CoV-2 variant stocks.Nat Protoc. 2023 Dec;18(12):3821-3855. doi: 10.1038/s41596-023-00897-6. Epub 2023 Oct 13. Nat Protoc. 2023. PMID: 37833423 Review.
-
Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.J Gen Virol. 2023 Mar;104(3):001831. doi: 10.1099/jgv.0.001831. J Gen Virol. 2023. PMID: 36857199 Free PMC article. Review.
-
Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review.Viruses. 2021 Dec 28;14(1):44. doi: 10.3390/v14010044. Viruses. 2021. PMID: 35062249 Free PMC article. Review.
-
Updates on Dengue Vaccine and Antiviral: Where Are We Heading?Molecules. 2021 Nov 9;26(22):6768. doi: 10.3390/molecules26226768. Molecules. 2021. PMID: 34833860 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
